Regulus Therapeutics ^{Priced, Nasdaq: RGLS}

Early stage biotech developing microRNAs treatments for multiple serious diseases.

Industry: Health Care

First Day Return: +5.0%

RGLS

Early stage biotech developing microRNAs treatments for multiple serious diseases.

IPO News for Regulus Therapeutics

Active week for IPOs marred by lackluster trading 10/05/12
Regulus Therapeutics prices IPO at $4.00 as expected 10/04/12
8 US IPOs planned for the week of Oct 1 10/01/12

IPO Data
IPO Date	10/04/2012
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$45
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	San Diego, CA, United States
Founded	2007
Employees at IPO	56
Website www.regulusrx.com

IPO News for Regulus Therapeutics

Active week for IPOs marred by lackluster trading 10/05/12
Regulus Therapeutics prices IPO at $4.00 as expected 10/04/12
8 US IPOs planned for the week of Oct 1 10/01/12

Regulus Therapeutics (RGLS) Performance